• 1
    Ware JE Jr. Standards for validating health measures: definition and content. J. Chronic Dis. 1987; 40: 47380.
  • 2
    Torrance GW. Utility approach to measuring health-related quality of life. J. Chronic Dis. 1987; 40: 593603.
  • 3
    Fitzpatrick R, Fletcher A, Gore S, Jones D, Spiegelhalter D, Cox D. Quality of life measures in health care. I: Applications and issues in assessment. BMJ 1992; 305: 10747.
  • 4
    Davis GL, Balart LA, Schiff ER et al. Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile. Clin. Ther. 1994; 16: 33443; discussion 271–2.
  • 5
    Hunt CM, Dominitz JA, Bute BP, Waters B, Blasi U, Williams DM. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Dig. Dis. Sci. 1997; 42: 24826.
  • 6
    Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999; 29: 26470.
  • 7
    Neary MP, Cort S, Bayliss MS, Ware JE Jr. Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Semin. Liver Dis. 1999; 19 (Suppl. 1): 7785.
  • 8
    Ware JE Jr, , Bayliss MS, Mannocchia M, Davis GL. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology 1999; 30: 5505.
  • 9
    McHutchison JG, Ware JE Jr, , Bayliss MS et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J. Hepatol. 2001; 34: 1407.
  • 10
    Law MG, Dore GJ, Bath N et al. Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. Int. J. Epidemiol. 2003; in press.
  • 11
    National Centre in, HIV, Epidemiology and Clinical Research (NCHECR). HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia. Annual Surveillance Report 2001. Sydney: NCHECR; 2002.
  • 12
    Dore GJ, Freeman AJ, Law M, Kaldor JM. Is severe liver disease a common outcome for people with chronic hepatitis C? J. Gastroenterol. Hepatol. 2002; 17: 42330.
  • 13
    Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 20912.
  • 14
    Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999; 30: 1299301.
  • 15
    Miller ER, Hiller JE, Shaw DR. Quality of life in HCV-infection: lack of association with ALT levels. Aust. NZ J. Public Health 2001; 25: 35561.
  • 16
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 82532.
  • 17
    Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N. Engl. J. Med. 1999; 340: 122833.
  • 18
    Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 2000; 32: 916.
  • 19
    Shiratori Y, Imazeki F, Moriyama M et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann. Intern. Med. 2000; 132: 51724.
  • 20
    Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 142632.
  • 21
    Fontana RJ, Moyer CA, Sonnad S et al. Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. Am. J. Gastroenterol. 2001; 96: 1708.
    Direct Link:
  • 22
    Hussain KB, Fontana RJ, Moyer CA, Su GL, Sneed-Pee N, Lok AS. Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C. Am. J Gastroenterol. 2001; 96: 273744.
    Direct Link:
  • 23
    Fontana RJ, Hussain KB, Schwartz SM, Moyer CA, Su GL, Lok AS. Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. J. Hepatol. 2002; 36: 4017.
  • 24
    Gifford SM, O'Brien ML, Bammer G, Banwell C, Stoove M. Australian women's experiences of living with hepatitis C virus: Results from a cross-sectional survey. J. Gastroenterol. Hepatol. 2003; 18: 84150.
  • 25
    O'Neill ES, Morrow LL. The symptom experience of women with chronic illness. J. Adv. Nurs. 2001; 33: 25768.
  • 26
    Hibbard JH, Pope CR. Gender roles, illness orientation and use of medical services. Soc. Sci. Med. 1983; 17: 12937.
  • 27
    Hibbard JH, Pope CR. Another look at sex differences in the use of medical care: illness orientation and the types of morbidities for which services are used. Women Health 1986; 11: 2136.
  • 28
    Macintyre S, Ford G, Hunt K. Do women ‘over-report’ morbidity? Men's and women's responses to structured prompting on a standard question on long standing illness. Soc. Sci. Med. 1999; 48: 8998.
  • 29
    Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med. Care 1996; 34: 22033.
  • 30
    Australian Bureau of Statistics (ABS). Mental Health and Well-Being Profile of Adults, Australia, 1997. Canberra: Australian Government Publishing Service, 1998.
  • 31
    Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center, 2000.